Results 11 to 20 of about 1,171,277 (292)
New England Journal of Medicine, 2020 Immune thrombocytopenia (ITP) is characterized by immune mediated platelet destruction in the body. Autoantibodies are formed directed against platelet surface membrane glycoproteins; antibody coated platelets are removed from circulation by the ...
Shamsi, Tahir Sultan
core +3 more sources
Pathogenesis of immune thrombocytopenia
Autoimmunity Reviews, 2017 International audienceImmune thrombocytopenia (ITP) is a rare autoimmune disease due to an abnormal T cell response, notably supported by splenic T follicular helper cells, that stimulates the proliferation and differentiation of autoreactive B cells ...
Matthieu Mahévas +9 more
core +3 more sources
Research Progress on Mechanism of Tumor-Associated Immune Thrombocytopenia [PDF]
Zhongliu Fangzhi YanjiuThrombocytopenia is a common complication during the treatment of malignant tumors. It can lead to insufficient doses of chemotherapy drugs or delayed chemotherapy, shorten patients’ survival time, and affect prognosis.
Guimin LIU +3 more
doaj +2 more sources
Immune thrombocytopenia in tuberculosis: Causal or coincidental?
Journal of Global Infectious Diseases, 2014 Immune thrombocytopenia is a relatively rare hematological manifestation in tuberculosis. We report two cases of immune thrombocytopemia, one in sputum positive pulmonary tuberculosis and the other in miliary tuberculosis.
Gopalakrishnan Srividya +3 more
doaj +2 more sources
Sovleplenib in immune thrombocytopenia
The Lancet HaematologyRefers to: Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study. https://doi.org/10.1016/S2352-3026(24)00139-XPeer
Mingot-Castellano, María Eva
core +3 more sources
New England Journal of Medicine, 2019 This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors’ clinical recommendations.
Cooper, Nichola, Ghanima, Waleed Khalid
+6 more sources
Hematology, 2010 Immune thrombocytopenia (ITP) comprises a heterogeneous group of disorders characterized by autoimmune-mediated platelet destruction and impairment of thrombopoiesis. ITP may occur in the absence of an evident predisposing etiology (primary ITP) or secondary to a growing list of associated conditions (secondary ITP), and must be differentiated from ...
Adam, Cuker, Douglas B, Cines
openaire +2 more sources
Immune Dysregulation in Immune Thrombocytopenia [PDF]
Seminars in Hematology, 2013 Immune thrombocytopenia (ITP) is a bleeding disorder characterized by low platelet counts due to decreased platelet production as well as increased platelet destruction by autoimmune mechanisms. A shift toward Th1 and possibly Th17 cells together with impaired regulatory compartment, including T-regulatory (Tregs) and B-regulatory (Bregs) cells, have ...
Karina, Yazdanbakhsh +2 more
openaire +2 more sources
Biomarkers for immune thrombocytopenia [PDF]
Biomarker Research, 2015 Immune thrombocytopenia is an autoimmune disease with abnormal biomarkers. Immune thrombocytopenia pathogenesis is a complicated process in which the patient's immune system is activated by platelet autoantigens resulting in immune mediated platelet destruction or suppression of platelet production.
Yu, Lingjia +4 more
openaire +2 more sources
Disease pathogenesis, treatment effectiveness, and co-morbid burden among adult patients with primary immune thrombocytopenia (ITP) [PDF]
, 2011 Background Primary immune thrombocytopenia (ITP) is an autoimmune disease involving autoantibody-mediated platelet destruction, suboptimal platelet production, and T-cell-mediated platelet lysis.
core +2 more sources